Clinical trial
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With…
NCT00003568 · University of Illinois at Chicago, Other · Completed
Key facts
| NCT number | NCT00003568 |
|---|---|
| Title | Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma |
| Official title | A Randomized Phase II Trial of a Mutated gp100 Melanoma Peptide (g209-217(210M) With Hight Dose Interleukin-2 (IL-2) in HLA-A2.1+Patients With Metastatic Melanoma |
| Lead sponsor | University of Illinois at Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, gp100 antigen, incomplete Freund's adjuvant |
| Start date | Nov 1, 1998 |
| Completion | Dec 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: